FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/8/2026
- Wall St futures decline as oil surge, high yields stoke inflation worries
- Oil jumps as Middle East supply concerns persist amid shipping attacks
- Goldman Sachs sees 18% upside for Palantir on sovereign AI growth
- Jefferies upgrades Royal Caribbean on stronger yield growth outlook
- Want to be a stock market bear? BCA says watch potential U.S. tax increases
Cullinan Therapeutics doses first patient in phase 2 AML study
Tweet Send to a Friend
Cullinan Therapeutics, Inc. (Nasdaq: CGEM) announced that the first patient has been dosed in a pivotal Phase 2 study of ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
